Funding for this research was provided by:
National Natural Science Foundation of China (Nos. 81772629)
Demonstrative Research Platform of Clinical Evaluation Technology for New Anticancer Drugs (No. 2018ZX09201015)
Tianjin Science Foundation (Nos. 18JCYBJC92000)
the Science & Technology Development Fund of the Tianjin Education Commission for Higher Education (2018KJ046)
Article History
Received: 18 April 2020
Accepted: 24 July 2020
First Online: 31 July 2020
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: All animal studies were performed by skilled laboratory personnel with the approval of the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital (Tianjin, China), and informed consent was obtained from all patients. All experimental procedures were performed under approved protocols following the principles and procedures outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
: Written informed consent was obtained from the parents.
: The authors affirm that human research participants provided informed consent for the publication of the image in Fig. InternalRef removed.
: The funders had no role in the study design, the data collection and analysis, interpretation of the data, the writing of the report, and the decision to submit this article for publication.